DFS: hormone receptor‐negativemedian · patients with early breast cancer
Capecitabine‐containing regimens probably leads to lower DFS: hormone receptor‐negativemedian compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
Overall survival: Median length of · patients with early breast cancer
Capecitabine‐containing regimens probably leads to lower overall survival (OS)median compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
Febrile neutropenia · patients with early breast cancer
Capecitabine‐containing regimens probably leads to lower febrile neutropenia compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
Diarrhoea · patients with early breast cancer
Capecitabine‐containing regimens probably leads to higher diarrhoea compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
Hand‐foot syndrome · patients with early breast cancer
Capecitabine‐containing regimens probably leads to higher hand‐foot syndrome compared with non‐capecitabine‐containing regimens or no chemotherapy (moderate certainty).
1 finding from 1 review
Specificity for detection of enamel caries · Asymptomatic children, adolescents, or adults presenting for clinical examination (in vivo studies), or extracted teeth of children or…
1 finding from 1 review
Diagnostic accuracy on surfaces with pit and fissure sealants · Asymptomatic children, adolescents, or adults presenting for clinical examination (in vivo studies), or extracted teeth of children or…
The review found no eligible studies for this question.
1 finding from 1 review
Sensitivity for detection of enamel caries · Asymptomatic children, adolescents, or adults presenting for clinical examination (in vivo studies), or extracted teeth of children or…
1 finding from 1 review
Disability due to FAP progression Not measured · people with early‐stage TTR‐FAP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity of peripheral neuropathy (expressed as the change in NIS‐LL) Scale from: 0 (normal) to 88 (total impairment) · people with early‐stage TTR‐FAP
1 finding from 1 review
QoL · people with early‐stage TTR‐FAP
1 finding from 1 review
Has died · people with early‐stage TTR‐FAP
It is very uncertain whether tafamidis changes number of participants who died during the trial compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with early‐stage TTR‐FAP
It is very uncertain whether tafamidis changes number of dropouts due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Number of participants experiencing at least one severe adverse event · people with early‐stage TTR‐FAP
It is very uncertain whether tafamidis changes number of participants experiencing at least one severe adverse event compared with placebo (very low certainty).
1 finding from 1 review
Primary outcomes · infants at risk for, or having early symptoms consistent with, opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
– Modifying environmental stimulation · infants at risk for, or having early symptoms consistent with, opioid withdrawal
1 finding from 1 review
– Feeding practices · infants at risk for, or having early symptoms consistent with, opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
– Support of the mother‐infant dyad · infants at risk for, or having early symptoms consistent with, opioid withdrawal
1 finding from 1 review
Admission to NICU (primary outcome)№ of participants: 204(1 RCT) · infants at risk for, or having early symptoms consistent with, opioid withdrawal
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Curea · people with Buruli ulcer, early lesions measuring less than 10 cm in diameter, aged 5 years or older
Rifampicin with clarithromycin showed no clear difference in curea compared with rifampicin with streptomycin (low certainty).
1 finding from 1 review